Literature DB >> 15489650

Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus.

Shinichi Ban1, Mari Mino, Norman S Nishioka, William Puricelli, Lawrence R Zukerberg, Michio Shimizu, Gregory Y Lauwers.   

Abstract

The efficacy of photodynamic therapy (PDT) is currently evaluated for the treatment of superficial neoplasms arising in Barrett's esophagus (BE). An accurate assessment of this technique requires the evaluation of biopsies before and after treatment. However, despite the importance of pathology, only a limited number of studies have systematically assessed the mucosal changes after PDT. To evaluate mucosal changes after PDT, and pathologic variables that may impact on the success of this therapy, we analyzed the pre- and post-PDT biopsies of a cohort of patients treated by this modality. Thirty-three patients (mean age, 71 years) with high-grade dysplasia (HGD) and/or intramucosal carcinoma (IMC) arising in BE and followed up after PDT using Porfimer sodium form the basis of this study. In all patients, a review of all pre- and post-PDT biopsies was performed. The variables recorded included the histologic grade and architecture of neoplasms, the distribution of neoplasms, and squamous re-epithelialization. IMC and HGD coexisted in the pre-PDT biopsies of 18 patients (54.5%). IMC and HGD showed a prominent tubular proliferation in 14 patients and displayed a papillary pattern (at least partially) in 19 patients. In post-PDT, patches of specialized columnar epithelium were buried under squamous epithelium in 17 patients (51.5%), and foci of dysplasia/carcinoma covered by squamous epithelium were found in 9 patients (27.3%). HGD and/or IMC were eradicated in 17 patients (eradicated group) and persisted in 16 patients (persistent group). In the persistent group, grade and architecture were unchanged after PDT in 62.5% and 87.5% of patients, respectively. The persistent group was characterized by: 1) a more frequent papillary architecture (P < 0.05), and 2) a diffuse distribution of the neoplasms on pre-PDT biopsies (P = 0.05). Singularly, the persistent neoplastic lesions were observed in the distal esophagus (P < 0.05). A systematic histopathologic evaluation allowed us to draw attention to the fact that distally located and papillary-type neoplasia seem resistant to PDT. The higher than expected incidence of buried residual neoplastic epithelium should also be emphasized since it represents a risk for undetected growth of malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489650     DOI: 10.1097/01.pas.0000141392.91677.7f

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

Review 3.  Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Authors:  Nathan A Gray; Robert D Odze; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2011-08-09       Impact factor: 10.864

Review 4.  Endoscopic treatments for dysplastic Barrett's esophagus: resection, ablation, what else?

Authors:  Charumathi Raghu Subramanian; George Triadafilopoulos
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 5.  Endoscopic management of Barrett esophagus.

Authors:  Aparna Repaka; Amitabh Chak
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-09-06       Impact factor: 46.802

Review 6.  Squamous intraepithelial neoplasia of the esophagus: past, present, and future.

Authors:  Michio Shimizu; Koji Nagata; Hiroshi Yamaguchi; Hiroto Kita
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

Review 7.  Mucosal ablation of Barrett esophagus.

Authors:  Irving Waxman; Vani J A Konda
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

8.  How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus.

Authors:  Gary D Mackenzie; Neil F Jamieson; Marco R Novelli; C Alexander Mosse; Benjamin R Clark; Sally M Thorpe; Stephen G Bown; Laurence B Lovat
Journal:  Lasers Med Sci       Date:  2007-07-03       Impact factor: 3.161

Review 9.  Management strategies of Barrett's esophagus.

Authors:  Giovanni D De Palma
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

10.  Barrett's esophagus: review of diagnosis and treatment.

Authors:  Raja Shekhar Sappati Biyyani; Amithab Chak
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.